The group wants to improve on its own Welireg in a new phase 3 trial.
ApexOnco Front Page
Recent articles
Replimune gets a second chance, while Sarclisa could go subcutaneous.
The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
Talapro-3 could help move Talzenna into earlier prostate cancer.
The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April.
Single, double and even triple-payload ADCs will be presented at the meeting.
First human data on MK-2010 are imminent.
The company reveals its anti-GPRC5D T-cell engager.
